Stem Cell Models for Drug Discovery and Toxicology Studies

Human stem cells and their derivatives could provide virtually unlimited sources of tissue for a wide range of toxicity models that could complement conventional animal models with more relevant, humanized versions. Human embryonic stem cells (hESCs) have already been proven valuable for drug/toxicity screens and mechanistic studies including analysis of disease pathway and developmental toxicity. Human‐induced pluripotent stem cells (iPSCs), which are generated by reprogramming somatic cells back to become hESC‐like cells, allow assays to be designed where the contribution of an individual's genetic background or environmental exposure history to toxicity response can be determined. Comprehensive profiling of hESC/iPSCs via genomics, proteomics, transcriptomics, and metabolomics could be used to elucidate pathway perturbations that underlie toxicity and disease, enabling the development of predictive assays for toxicity. While technological hurdles still exist for widespread use and implementation, incorporation of human stem cell based assays into drug discovery and toxicity testing offers the potential for safer, more customized medicines and more accurate risk assessment for environmental toxicants, as well as reduced costs and decreased use of animal models. We examine limitations and deficiencies of current toxicology approaches and how human stem cell based in vitro assays may overcome them. We describe how human stem cells are used for predictive toxicology. We also identify technological limitations that prevent stem cells from being integrated into standard practice, as well as new tools and technologies that may overcome them. We discuss research priorities that are most useful for transforming cell‐based toxicology models into reality, and research areas in which stem cell technology could make substantial contributions to the development and implementation of stem cell based models for toxicity testing. Increased use of human in vitro models of toxicity could reduce the use of animals in safety and risk assessment studies and offers the potential to dramatically enhance our understanding of the molecular basis of toxicity, leading to improved human models and assays for predicting biological response to drugs and environmental hazards. © 2012 Wiley Periodicals, Inc. J BiochemMol Toxicol 27:17‐27, 2013; View this article online at wileyonlinelibrary.com. DOI 10.1002/jbt.21470

[1]  Mary Anne Wheeler,et al.  Stem , 1985 .

[2]  R. Poretz,et al.  Lead exposure affects levels of galactolipid metabolic enzymes in the developing rat brain. , 2001, Toxicology and applied pharmacology.

[3]  R. McKinnon,et al.  Lead exposure delays the differentiation of oligodendroglial progenitors in vitro. , 2001, Toxicology and applied pharmacology.

[4]  R. Poretz,et al.  Lead alters the developmental profile of the galactolipid metabolic enzymes in cultured oligodendrocyte lineage cells. , 2001, Neurotoxicology.

[5]  R. Poretz,et al.  Protein kinase C activation is required for the lead-induced inhibition of proliferation and differentiation of cultured oligodendroglial progenitor cells , 2002, Brain Research.

[6]  R. Poretz,et al.  Oligodendroglia in developmental neurotoxicity. , 2003, Neurotoxicology.

[7]  F. Jensen,et al.  Calcium-permeable AMPA/kainate receptors mediate toxicity and preconditioning by oxygen-glucose deprivation in oligodendrocyte precursors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  F. Jensen,et al.  Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Pamela L. Follett,et al.  Glutamate Receptor-Mediated Oligodendrocyte Toxicity in Periventricular Leukomalacia: A Protective Role for Topiramate , 2004, The Journal of Neuroscience.

[10]  F. Jensen,et al.  Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function , 2006, Journal of neurochemistry.

[11]  F. Jensen,et al.  α-Amino-3-hydroxy-5-methyl-4-isoxazole Propionate Receptor Subunit Composition and cAMP-response Element-binding Protein Regulate Oligodendrocyte Excitotoxicity* , 2006, Journal of Biological Chemistry.

[12]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[13]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[14]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[15]  G. Korbutt,et al.  Generation of Insulin‐Producing Islet‐Like Clusters from Human Embryonic Stem Cells , 2007, Stem cells.

[16]  George Q. Daley,et al.  Reprogramming of human somatic cells to pluripotency with defined factors , 2008, Nature.

[17]  L. Rubin Stem Cells and Drug Discovery: The Beginning of a New Era? , 2008, Cell.

[18]  Shinya Yamanaka,et al.  Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors , 2008, Science.

[19]  Takashi Aoi,et al.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts , 2008, Nature Biotechnology.

[20]  Sheng Ding,et al.  A chemical approach to stem-cell biology and regenerative medicine , 2008, Nature.

[21]  K. Woltjen,et al.  Virus free induction of pluripotency and subsequent excision of reprogramming factors , 2009, Nature.

[22]  Wei Wang,et al.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells , 2009, Nature.

[23]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[24]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[25]  Dong Wook Han,et al.  Generation of induced pluripotent stem cells using recombinant proteins. , 2009, Cell stem cell.

[26]  T. Cantz,et al.  Induced pluripotent stem cells generated without viral integration , 2009, Hepatology.

[27]  W. Deng,et al.  Genome integrity: linking pluripotency and tumorgenicity. , 2009, Trends in genetics : TIG.

[28]  J. R. Holt,et al.  Differentiation of neurons from neural precursors generated in floating spheres from embryonic stem cells , 2009, BMC Neuroscience.

[29]  Robert Lanza,et al.  Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. , 2009, Cell stem cell.

[30]  W. Deng PARylation: strengthening the connection between cancer and pluripotency. , 2009, Cell stem cell.

[31]  Martin J. Aryee,et al.  Epigenetic memory in induced pluripotent stem cells , 2010, Nature.

[32]  X. Yang,et al.  Culture conditions and enzymatic passaging of bovine ESC-like cells. , 2010, Cellular reprogramming.

[33]  W. Deng Induced pluripotent stem cells: paths to new medicines , 2010, EMBO reports.

[34]  Ronald A. Li,et al.  Electrophysiological properties of human induced pluripotent stem cells. , 2010, American journal of physiology. Cell physiology.

[35]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[36]  W. Deng,et al.  Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies. , 2010, Trends in biotechnology.

[37]  W. Deng,et al.  Neurobiology of injury to the developing brain , 2010, Nature Reviews Neurology.

[38]  Krishanu Saha,et al.  Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues , 2010, Cell.

[39]  Mitsugu Sekimoto,et al.  Reprogramming of mouse and human cells to pluripotency using mature microRNAs. , 2011, Cell stem cell.

[40]  Yunfang Wang,et al.  Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue‐specific biomatrix scaffolds , 2011, Hepatology.

[41]  R. Ponce Safety assessment of immunomodulatory biologics: The promise and challenges of regulatory T-cell modulation , 2011, Journal of immunotoxicology.

[42]  Andrew P. Feinberg,et al.  Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells , 2011, Nature Biotechnology.

[43]  S. Przyborski,et al.  Neuropharmacological properties of neurons derived from human stem cells , 2011, Neurochemistry International.

[44]  Sui Huang,et al.  Systems biology of stem cells: three useful perspectives to help overcome the paradigm of linear pathways , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.

[45]  Ying Liu,et al.  OLIG gene targeting in human pluripotent stem cells for motor neuron and oligodendrocyte differentiation , 2011, Nature Protocols.

[46]  E. Heinzle,et al.  In‐depth physiological characterization of primary human hepatocytes in a 3D hollow‐fiber bioreactor , 2011, Journal of tissue engineering and regenerative medicine.

[47]  Mudit Gupta,et al.  Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. , 2011, Cell stem cell.

[48]  M. Götz,et al.  Generation of subtype-specific neurons from postnatal astroglia of the mouse cerebral cortex , 2011, Nature Protocols.

[49]  Naoki Nishishita,et al.  Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors , 2011, Proceedings of the National Academy of Sciences.

[50]  Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability , 2012, Genome Medicine.

[51]  Kitai Kim,et al.  Generating pluripotent stem cells: Differential epigenetic changes during cellular reprogramming , 2012, FEBS letters.

[52]  Bikram Singh,et al.  Thalidomide: chemistry, therapeutic potential and oxidative stress induced teratogenicity. , 2012, Current topics in medicinal chemistry.

[53]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[54]  G Duker,et al.  Comparison of the IKr blockers moxifloxacin, dofetilide and E‐4031 in five screening models of pro‐arrhythmia reveals lack of specificity of isolated cardiomyocytes , 2012, British journal of pharmacology.

[55]  W. Deng,et al.  Differentiating human stem cells into neurons and glial cells for neural repair. , 2012, Frontiers in bioscience.

[56]  A. Nagy,et al.  Genome damage in induced pluripotent stem cells: assessing the mechanisms and their consequences. , 2013, BioEssays : news and reviews in molecular, cellular and developmental biology.

[57]  H. Nakauchi,et al.  Stem cell therapy: an exercise in patience and prudence , 2013, Philosophical Transactions of the Royal Society B: Biological Sciences.